| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Vitamin K_2 Alters Bone Metabolism Markers in Hemodialysis Patients with a Low Serum Parathyroid Hormone Level |
|
言語 |
en |
| 作成者 |
Ochiai, Mariko
Nakashima, Ayumu
Takasugi, Norihisa
Kiribayashi, Kei
Kawai, Toru
Usui, Koji
Shigemoto, Kenichiro
Hamaguchi, Naoki
Kohno, Nobuoki
Yorioka, Noriaki
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
Copyright (c) 2010 S. Karger AG, Basel |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Vitamin K2 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Bone metabolism markers |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Intact parathyroid hormone |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Hemodialysis |
| 主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
| 内容記述 |
|
|
内容記述 |
Background: A low level of intact parathyroid hormone (PTH) is an indicator of adynamic bone disease in hemodialysis patients, and is associated with a significant increase of all-cause mortality. Thus, effective treatment for adynamic bone disease is required. We previously investigated the effect of vitamin K2 on adynamic bone disease. In this study, we assessed the efficacy of oral vitamin K2 in a controlled trial. Methods: Forty hemodialysis patients with low intact PTH levels (<100 pg/ml) were randomly divided into two groups, which were a vitamin K2 group receiving oral menatetrenone (45 mg/day) for 1 year and a control group without vitamin K2. Venous blood samples were collected at baseline and during the study for measurement of bone metabolism parameters. Results: Thirty-three patients completed follow-up. There was a significant increase of the serum intact osteocalcin level after 1 month of vitamin K2 administration. Serum levels of intact PTH, bone alkaline phosphatase, and cross-linked N-terminal telopeptide of type I collagen increased significantly after 12 months in the vitamin K2 group. The serum osteoprotegerin level was decreased after 12 months in the vitamin K2 group, but the change was not significant. Conclusion: Vitamin K2 therapy improves bone remodeling in hemodialysis patients with a low intact PTH level. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Karger |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1159/000319642 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
http://dx.doi.org/10.1159/000319642 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1660-2110 |
| 開始ページ |
|
|
開始ページ |
c15 |
| 書誌情報 |
Nephron Clinical Practice
Nephron Clinical Practice
巻 117,
号 1,
p. c15-c19,
発行日 2011
|
| 旧ID |
31183 |
NephronClinPract_117_c15.pdf (78.6 KB)
